Cargando…

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

BACKGROUND: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). T...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Jill A., Galaznik, Aaron, Pompilus, Farrah, Strzok, Sara, Bejar, Rafael, Scipione, Fatima, Fram, Robert J., Faller, Douglas V., Cano, Stefan, Marquis, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584583/
https://www.ncbi.nlm.nih.gov/pubmed/31218454
http://dx.doi.org/10.1186/s41687-019-0123-4
_version_ 1783428538710360064
author Bell, Jill A.
Galaznik, Aaron
Pompilus, Farrah
Strzok, Sara
Bejar, Rafael
Scipione, Fatima
Fram, Robert J.
Faller, Douglas V.
Cano, Stefan
Marquis, Patrick
author_facet Bell, Jill A.
Galaznik, Aaron
Pompilus, Farrah
Strzok, Sara
Bejar, Rafael
Scipione, Fatima
Fram, Robert J.
Faller, Douglas V.
Cano, Stefan
Marquis, Patrick
author_sort Bell, Jill A.
collection PubMed
description BACKGROUND: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study was to select supplemental items to add to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients with higher-risk (HR) MDS, low-blast count (LB) AML, and CMML, thus, improving the instrument’s ability to detect clinically meaningful treatment benefit for this context of use. METHODS: Our mixed methods approach comprised literature review, clinician consultation (n = 3), and qualitative and quantitative analysis of two stages of patient interview data (n = 14, n = 18) to select library bank items to supplement a generic cancer PRO, the EORTC QLQ-C30. RESULTS: Unique symptom (n = 54) and impact (n = 72) concepts were organized into conceptual frameworks of treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items (n = 13) addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items (n = 7 symptom; n = 3 impact) were selected for the MDS/AML/CMML context. CONCLUSION: Supplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the areas of fatigue, shortness of breath, and functioning.
format Online
Article
Text
id pubmed-6584583
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-65845832019-07-05 A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia Bell, Jill A. Galaznik, Aaron Pompilus, Farrah Strzok, Sara Bejar, Rafael Scipione, Fatima Fram, Robert J. Faller, Douglas V. Cano, Stefan Marquis, Patrick J Patient Rep Outcomes Research BACKGROUND: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study was to select supplemental items to add to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients with higher-risk (HR) MDS, low-blast count (LB) AML, and CMML, thus, improving the instrument’s ability to detect clinically meaningful treatment benefit for this context of use. METHODS: Our mixed methods approach comprised literature review, clinician consultation (n = 3), and qualitative and quantitative analysis of two stages of patient interview data (n = 14, n = 18) to select library bank items to supplement a generic cancer PRO, the EORTC QLQ-C30. RESULTS: Unique symptom (n = 54) and impact (n = 72) concepts were organized into conceptual frameworks of treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items (n = 13) addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items (n = 7 symptom; n = 3 impact) were selected for the MDS/AML/CMML context. CONCLUSION: Supplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the areas of fatigue, shortness of breath, and functioning. Springer International Publishing 2019-06-19 /pmc/articles/PMC6584583/ /pubmed/31218454 http://dx.doi.org/10.1186/s41687-019-0123-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Bell, Jill A.
Galaznik, Aaron
Pompilus, Farrah
Strzok, Sara
Bejar, Rafael
Scipione, Fatima
Fram, Robert J.
Faller, Douglas V.
Cano, Stefan
Marquis, Patrick
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
title A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
title_full A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
title_fullStr A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
title_full_unstemmed A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
title_short A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
title_sort pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the eortc item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584583/
https://www.ncbi.nlm.nih.gov/pubmed/31218454
http://dx.doi.org/10.1186/s41687-019-0123-4
work_keys_str_mv AT belljilla apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT galaznikaaron apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT pompilusfarrah apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT strzoksara apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT bejarrafael apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT scipionefatima apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT framrobertj apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT fallerdouglasv apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT canostefan apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT marquispatrick apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT belljilla pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT galaznikaaron pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT pompilusfarrah pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT strzoksara pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT bejarrafael pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT scipionefatima pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT framrobertj pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT fallerdouglasv pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT canostefan pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia
AT marquispatrick pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia